Izzy, I don't have the details, but I think that the CHIR suit is on PIs. I think that CHIR picked up PCR patents when they acquired Cetus, but I don't think that PCR has anything to do with the PI suits against AGPH, GILD, LLY, and a couple of others. They may have a general claim on using PI inhibitors to treat disease, but that's just a guess on my part.
If I had to guess about AGPH, I would say that it's main problem with the street is the fact that it is viewed as a one product company, and although that product is currently doing well, competition is coming from many directions which will slow growth.
In addition, AGPH is a biotech, and the sector is being hurt by institutions leaving (see WSJ article on T Rowe Price Health Science fund) as well as shorts taking advantage of the weakness. The weakness is also supported by many advanced product failures (at the Phase III or FDA approval level). The product failures have also made pharma partners a bit more jittery, especially as pressure grows for pipeline replacements. |
